Login to Your Account

Valor restored: Sunesis' vosaroxin subset shines; old hold key to new bid?

By Randy Osborne
Staff Writer

Friday, June 12, 2015
Company officials would not go into details, but Sunesis Pharmaceuticals Inc.'s drill-down on data from the narrowly failed phase III trial called Valor could mean the firm will take aim at patients ages 60 and beyond as regulatory efforts continue with the quinolone derivative vosaroxin plus cytarabine in adults with relapsed or refractory acute myeloid leukemia (AML).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription